Lenalidomide-OH

Cat. No.: HY-133144

CAS No.: 1416990-08-3

Molecular Formula: $C_{13}H_{12}N_2O_4$

Molecular Weight: 260.25

Target: Ligands for E3 Ligase

Pathway: PROTAC

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 13.89 mg/mL (53.37 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.8425 mL	19.2123 mL	38.4246 mL
	5 mM	0.7685 mL	3.8425 mL	7.6849 mL
	10 mM	0.3842 mL	1.9212 mL	3.8425 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 (HY-133137)[1].

IC_{50} & Target

Cereblon

In Vitro

Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of

ubiquitination-mediated degradation of cancer-promoting proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA